Study of EV for recurrent endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a drug called EV for people with recurrent endometrial cancer that has gotten worse after treatment. It may help if your cancer cells have a specific protein called nectin-4.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have endometrial cancer that has come back and is getting worse.
- You have had surgery (including hysterectomy) and platinum-based chemotherapy, and if eligible, immunotherapy.
- You have had up to 3 prior treatments for your cancer.
- Your cancer cells have the nectin-4 protein (checked via a test on a tumor sample).
- You are in generally good health (able to do daily activities, with adequate organ function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
This trial tests a new combination of drugs for endometrial cancer that has spread or come back. It aims to see if these drugs can shrink tumors and help people live longer. It is for tumors that have a certain protein (HER2) and are mismatch repair proficient (meaning they have a normal DNA repair system).
This trial tests a combination of three drugs (pembrolizumab, lenvatinib, and an immune booster called N-803) plus a personalized vaccine made from your own cells, all aimed at helping your immune system fight advanced or metastatic endometrial cancer that has HER2 protein on its surface.
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
This trial is testing an experimental therapy against standard chemotherapy for people with endometrial cancer that has come back. The study looks for a certain protein (HER2) on cancer cells to decide which treatment group you may be in.
This trial tests a drug called enfortumab vedotin for people with certain advanced thyroid cancers or NUT carcinoma that have not responded to other treatments. The drug is given by IV and aims to shrink or slow the cancer.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.